AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Vetoquinol SA

Report Publication Announcement Dec 15, 2015

1747_iss_2015-12-15_6a284ebd-34c9-4295-a603-75a74d9e56c0.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Press Release Lure (France), December 15, 2015

2016 CALENDAR OF FINANCIAL COMMUNICATION

December 15, 2015 (Lure, France) – Vétoquinol published its calendar of financial communication for 2016.

January 21, 2016 2015 Annual revenues (after market)
March 21, 2016 2015 Annual results (after market)
April 19, 2016 2016 First quarter revenues (after market)
May 24, 2016 Annual shareholders' meeting
June 6, 2016 Dividend distribution
July 28, 2016 2016 Interim revenues and interim results (after market)
October 18, 2016 2016 Third quarter revenues (after market)
January 26, 2017 2016 Annual revenues (after market)

Next update: 2015 Annual revenues – January 21, 2016 after market close

About Vétoquinol

Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs 2,024 people at June 30th, 2015. Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For further information, go to: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE

For any information, contact: VETOQUINOL KEIMA COMMUNICATION Investor Relations Marie-Josée Aubry-Rota Tel: +33 (0)3 84 62 59 88 [email protected]

Investor & Media Relations Emmanuel Dovergne Tel: +33 (0)1 56 43 44 63 [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.